| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.
|
Antimicrob Agents Chemother
|
1998
|
4.95
|
|
2
|
Detection of amphotericin B-resistant Candida isolates in a broth-based system.
|
Antimicrob Agents Chemother
|
1995
|
4.92
|
|
3
|
Taxonomy, biology, and clinical aspects of Fusarium species.
|
Clin Microbiol Rev
|
1994
|
3.58
|
|
4
|
Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management.
|
Blood
|
1997
|
3.45
|
|
5
|
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
|
Clin Infect Dis
|
1998
|
3.09
|
|
6
|
International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.
|
Eur J Clin Microbiol Infect Dis
|
2005
|
2.34
|
|
7
|
Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal.
|
Blood
|
1995
|
2.23
|
|
8
|
Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management.
|
Clin Infect Dis
|
1993
|
2.17
|
|
9
|
Regulation of cryptococcal capsular polysaccharide by iron.
|
J Infect Dis
|
1993
|
2.03
|
|
10
|
Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.
|
Antimicrob Agents Chemother
|
2001
|
2.03
|
|
11
|
The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside.
|
Clin Infect Dis
|
1996
|
2.03
|
|
12
|
Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia.
|
Clin Infect Dis
|
2001
|
1.88
|
|
13
|
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
|
Bone Marrow Transplant
|
2006
|
1.85
|
|
14
|
Importance of Candida species other than Candida albicans as opportunistic pathogens.
|
Med Mycol
|
1998
|
1.55
|
|
15
|
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses.
|
Clin Infect Dis
|
2001
|
1.48
|
|
16
|
Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion.
|
Eur J Clin Microbiol Infect Dis
|
2001
|
1.39
|
|
17
|
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients.
|
Bone Marrow Transplant
|
2006
|
1.35
|
|
18
|
Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility.
|
J Clin Microbiol
|
1999
|
1.32
|
|
19
|
Bronchoalveolar lavage in the diagnosis of pulmonary infiltrates in patients with acute leukemia.
|
Chest
|
1988
|
1.31
|
|
20
|
A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.
|
Arch Intern Med
|
1992
|
1.21
|
|
21
|
Effects of broad-spectrum antimicrobial agents on yeast colonization of the gastrointestinal tracts of mice.
|
Antimicrob Agents Chemother
|
1990
|
1.20
|
|
22
|
Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice.
|
J Infect Dis
|
1993
|
1.19
|
|
23
|
Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans.
|
Antimicrob Agents Chemother
|
1993
|
1.18
|
|
24
|
Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. A new spectrum.
|
Ann Intern Med
|
1994
|
1.15
|
|
25
|
A model of sustained gastrointestinal colonization by Candida albicans in healthy adult mice.
|
Infect Immun
|
1990
|
1.12
|
|
26
|
Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated.
|
Arch Intern Med
|
1996
|
1.11
|
|
27
|
Chronic systemic candidiasis.
|
Eur J Clin Microbiol Infect Dis
|
1989
|
1.09
|
|
28
|
Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study.
|
Leukemia
|
1997
|
1.07
|
|
29
|
Treatment of murine fusariosis with SCH 56592.
|
Antimicrob Agents Chemother
|
1999
|
1.07
|
|
30
|
Fungal infections in iatrogenically compromised hosts.
|
Adv Intern Med
|
1998
|
0.97
|
|
31
|
Trial design for mold-active agents: time to break the mold--aspergillosis in neutropenic adults.
|
Clin Infect Dis
|
2007
|
0.94
|
|
32
|
Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.
|
Clin Infect Dis
|
1997
|
0.94
|
|
33
|
Iron acquisition by Cryptococcus neoformans.
|
J Med Vet Mycol
|
1995
|
0.93
|
|
34
|
Rhinocerebral mucormycosis with internal carotid occlusion: report of two cases and review of the literature.
|
Laryngoscope
|
1985
|
0.93
|
|
35
|
Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET).
|
Transpl Infect Dis
|
2014
|
0.93
|
|
36
|
Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B.
|
Cancer
|
1994
|
0.91
|
|
37
|
Aspergillus fumigatus conidia induce a Th1-type cytokine response.
|
J Infect Dis
|
1997
|
0.91
|
|
38
|
Problems and controversies in the management of hematogenous candidiasis.
|
Clin Infect Dis
|
1996
|
0.91
|
|
39
|
Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients.
|
Bone Marrow Transplant
|
2006
|
0.90
|
|
40
|
Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients.
|
Cancer Immunol Immunother
|
1998
|
0.90
|
|
41
|
Infections due to Cunninghamella bertholletiae in patients with cancer: report of three cases and review.
|
Clin Infect Dis
|
1994
|
0.89
|
|
42
|
Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography.
|
Antimicrob Agents Chemother
|
1995
|
0.86
|
|
43
|
Investigation of an outbreak of gram-negative bacteremia among hematology-oncology outpatients.
|
Infect Control Hosp Epidemiol
|
2000
|
0.86
|
|
44
|
SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice.
|
Antimicrob Agents Chemother
|
1995
|
0.85
|
|
45
|
Cytokines as therapy for opportunistic fungal infections.
|
Res Immunol
|
1998
|
0.85
|
|
46
|
Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection.
|
J Clin Apher
|
1995
|
0.85
|
|
47
|
Protection of human polymorphonuclear leukocyte function from the deleterious effects of isolation, irradiation, and storage by interferon-gamma and granulocyte-colony-stimulating factor.
|
Transfusion
|
1995
|
0.83
|
|
48
|
Branhamella catarrhalis septicemia in patients with leukemia.
|
Cancer
|
1988
|
0.82
|
|
49
|
Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature.
|
J Neurosurg
|
1997
|
0.82
|
|
50
|
Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice.
|
Antimicrob Agents Chemother
|
1994
|
0.82
|
|
51
|
Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis.
|
Antimicrob Agents Chemother
|
1996
|
0.82
|
|
52
|
Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections.
|
Antimicrob Agents Chemother
|
1995
|
0.82
|
|
53
|
Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults.
|
Leukemia
|
2002
|
0.81
|
|
54
|
Predictors of outcome in cancer patients with candidemia.
|
Ann Oncol
|
2000
|
0.81
|
|
55
|
The role of immunoreconstitution in the management of refractory opportunistic fungal infections.
|
Med Mycol
|
1998
|
0.81
|
|
56
|
Malassezia and Trichosporon: two emerging pathogenic basidiomycetous yeast-like fungi.
|
J Med Vet Mycol
|
1994
|
0.80
|
|
57
|
Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
|
Bone Marrow Transplant
|
2004
|
0.80
|
|
58
|
Update on invasive candidiasis.
|
Adv Pharmacol
|
1997
|
0.80
|
|
59
|
The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed?
|
Clin Infect Dis
|
1998
|
0.79
|
|
60
|
Incidence of imipenem hypersensitivity reactions in febrile neutropenic bone marrow transplant patients with a history of penicillin allergy.
|
Clin Infect Dis
|
2000
|
0.79
|
|
61
|
Effects of cyclophosphamide and ceftriaxone on gastrointestinal colonization of mice by Candida albicans.
|
Antimicrob Agents Chemother
|
1996
|
0.79
|
|
62
|
Septic prepatellar bursitis caused by Stenotrophomonas (Xanthomonas) maltophilia.
|
Clin Infect Dis
|
1996
|
0.79
|
|
63
|
Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients.
|
Transpl Infect Dis
|
2013
|
0.78
|
|
64
|
Stenotrophomonas maltophilia: an unusual cause of biliary sepsis.
|
Clin Infect Dis
|
1995
|
0.78
|
|
65
|
Activated lymphocytes reduce adherence of Aspergillus fumigatus.
|
Med Mycol
|
1998
|
0.77
|
|
66
|
Is it time to redefine the management of febrile neutropenia in cancer patients?
|
Am J Med
|
1995
|
0.77
|
|
67
|
The clinical spectrum of stenotrophomonas (xanthomonas) maltophilia respiratory infection.
|
Semin Respir Crit Care Med
|
2000
|
0.76
|
|
68
|
gamma-Cyclodextrin:testosterone complex suitable for sublingual administration.
|
J Pharm Sci
|
1987
|
0.76
|
|
69
|
Outpatient therapy for febrile neutropenia: who, when, and how?
|
J Antimicrob Chemother
|
1999
|
0.75
|
|
70
|
Effects of in vitro and in vivo cytokine treatment, leucapheresis and irradiation on the function of human neutrophils: implications for white blood cell transfusion therapy.
|
Clin Lab Haematol
|
1997
|
0.75
|
|
71
|
Fluconazole.
|
J Med Vet Mycol
|
1992
|
0.75
|
|
72
|
Single agent therapy for infections in cancer patients: a prospective randomized trial comparing three extended-spectrum cephalosporins.
|
Eur J Clin Microbiol Infect Dis
|
1991
|
0.75
|
|
73
|
Acute fungal thyroiditis in a patient with acute myelogenous leukaemia.
|
J Intern Med
|
1991
|
0.75
|